NCT03689192View on ClinicalTrials.gov

Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 17, 2018

Primary Completion Date

January 19, 2022

Study Completion Date

January 19, 2022

Conditions

Non Small Cell Lung CancerUrothelial CarcinomaMalignant MelanomaOvarian CancerColorectal CancerBreast CancerSquamous Cell Carcinoma of the Head and NeckMetastatic Cancer

Interventions

BIOLOGICAL

ARG1-18,19,20

300 ug ARG1-18,19,20 peptide in water mixed with 500ul montanide

Trial Locations (1)

2730

Center for Cancer Immune Therapy Dept. of Hematology/oncology, Copenhagen

All Listed Sponsors

lead

Herlev Hospital

OTHER

NCT03689192 - Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter